ECOG-ACRIN (E-A) represents the merger of ECOG and ACRIN to form a cooperative group focused on practice-changing clinical and translational research across the cancer care continuum from prevention and early detection, through the management of advanced disease and its impact. This NCORP Research Base application represents an ambitious program that continues the E-A legacy of community based, high impact research in cancer prevention and early detection, and in embedding patient-centered outcomes into therapeutic trials, and extends our traditional research base activities to include an expanded emphasis on studying disparities, the unique needs of older and younger adults diagnosed with cancer, and cancer care delivery research. There is particular emphasis on the relationship between early detection and therapy of early disease in an effort to reduce morbidity of overtreatment. There is also an emphasis on studying the biology that drives symptoms and toxicity with a particular focus on cardiotoxicity and taxane related neuropathy. Key collaborations with community-based oncology programs will ensure access to E-A NCORP trials in communities where patients receive their care. Leveraging existing NCI-funded resources as well as a network of >10000 physicians, scientists, nurses, research associates (RAs), statisticians, biomedical information technologists, and patient advocates across approximately 600 institutions and organizations, E-A is poised to make significant contributions as a member of the NCORP community.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Program Officer
Xie, Heng
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ecog-Acrin Medical Research Foundation
United States
Zip Code
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Morgans, Alicia K; Chen, Yu-Hui; Sweeney, Christopher J et al. (2018) Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095
Cohee, Andrea A; Bigatti, Silvia M; Shields, Cleveland G et al. (2018) Quality of Life in Partners of Young and Old Breast Cancer Survivors. Cancer Nurs 41:491-497
Yeruva, Sri Lakshmi Hyndavi; Zhao, Fengmin; Miller, Kathy D et al. (2018) E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer 4:1
Charkhchi, Paniz; Fazeli Dehkordy, Soudabeh; Carlos, Ruth C (2018) Housing and Food Insecurity, Care Access, and Health Status Among the Chronically Ill: An Analysis of the Behavioral Risk Factor Surveillance System. J Gen Intern Med 33:644-650
Gee, Michael S; Atri, Mostafa; Bandos, Andriy I et al. (2018) Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial. Radiology 287:176-184
Gareen, Ilana F; Black, William C; Tosteson, Tor D et al. (2018) Medical Care Costs Were Similar Across the Low-dose Computed Tomography and Chest X-Ray Arms of the National Lung Screening Trial Despite Different Rates of Significant Incidental Findings. Med Care 56:403-409
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Boxerman, Jerrold L; Zhang, Zheng; Safriel, Yair et al. (2018) Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. Neuro Oncol 20:1400-1410
Zhao, Fengmin; Cella, David; Manola, Judith et al. (2018) Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. Support Care Cancer 26:1889-1895

Showing the most recent 10 out of 100 publications